Want to see JP:4547 full AI Analyst Report?
Top Page
Kissei Pharmaceutical Co
(4547)
Select Model
Select Model
Rating:64Neutral
Price Target:
¥4,457.00
▲(5.12% Upside)
Action:Reiterated
Date:08/17/26
The score is driven primarily by solid financial stability from an exceptionally low-leverage balance sheet and improving multi-year revenue trends, partially offset by inconsistent and often negative cash flow and a recent decline in operating performance. Technically, indicators are mostly neutral with mixed moving-average trends, while valuation is supportive due to a moderate P/E and a ~2.7% dividend yield.
Positive Factors
Low-Leverage Balance Sheet
Conservative leverage gives Kissei substantial financial flexibility and resilience during earnings volatility. A strong equity and asset base can support continued research, product development, partnerships, and operations without heavy dependence on external financing.
Negative Factors
Weak Cash Conversion
Unreliable conversion of accounting earnings into operating and free cash flow can constrain investment, dividends, and business development. Persistent working-capital swings or cash costs may reduce the practical value of reported profitability over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low-Leverage Balance Sheet
Conservative leverage gives Kissei substantial financial flexibility and resilience during earnings volatility. A strong equity and asset base can support continued research, product development, partnerships, and operations without heavy dependence on external financing.
Read all positive factors
Kissei Pharmaceutical Co (4547) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥166.45B
Dividend Yield2.74%
Average Volume (3M)67.88K
Price to Earnings (P/E)12.2
Beta (1Y)0.55
Revenue Growth10.35%
EPS Growth16.60%
CountryJP
Employees1,786
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)337.39
Shares Outstanding46,541,985
10 Day Avg. Volume76,260
30 Day Avg. Volume67,883
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)0.84
Price to Sales (P/S)1.98
P/FCF Ratio-30.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥4,020.00Price Target Upside-5.19% Downside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)280.87
Revenue Forecast (FY)¥92.30B
Kissei Pharmaceutical Co Business Overview & Revenue Model
Company Description
Kissei Pharmaceutical Co., Ltd. specializes in the discovery, development, production, and commercialization of pharmaceutical products, with a primary focus on the Japanese market. Its marketed pharmaceuticals encompass Urief and Urief OD tablets...
How the Company Makes Money
Kissei primarily makes money by selling prescription pharmaceuticals, generating revenue from product sales to medical institutions and via pharmaceutical distribution channels in its core market (primarily Japan). A second revenue stream comes fr...
Kissei Pharmaceutical Co Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
88
Very Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 98.60B | 97.41B | 88.33B | 75.58B | 67.49B | 65.38B |
| Gross Profit | 46.17B | 45.82B | 44.06B | 37.34B | 32.38B | 31.24B |
| EBITDA | 16.90B | 21.56B | 20.25B | 18.72B | 17.81B | 20.26B |
| Net Income | 13.98B | 13.78B | 11.96B | 11.16B | 10.53B | 12.92B |
Balance Sheet | ||||||
| Total Assets | 270.24B | 275.09B | 244.06B | 260.93B | 221.20B | 238.09B |
| Cash, Cash Equivalents and Short-Term Investments | 52.95B | 54.42B | 48.65B | 45.93B | 49.60B | 53.15B |
| Total Debt | 1.72B | 1.25B | 1.60B | 1.73B | 1.95B | 1.98B |
| Total Liabilities | 39.79B | 43.55B | 33.93B | 39.79B | 26.38B | 35.91B |
| Stockholders Equity | 229.03B | 230.15B | 209.00B | 220.03B | 193.90B | 201.39B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -6.37B | 2.01B | -2.88B | -8.78B | 44.00M |
| Operating Cash Flow | 0.00 | -1.49B | 6.52B | -1.68B | -6.68B | 1.53B |
| Investing Cash Flow | 0.00 | 17.50B | 4.95B | 8.69B | 6.00B | 10.78B |
| Financing Cash Flow | 0.00 | -10.26B | -9.32B | -10.01B | -3.42B | -2.76B |
Kissei Pharmaceutical Co Technical Analysis
Positive
4240.00
Price Trends
4097.40
Positive
4199.35
Negative
4334.49
Negative
Market Momentum
-4.18
Positive
50.68
Neutral
24.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4547, the sentiment is Positive. The current price of 4240 is above the 20-day moving average (MA) of 4087.25, above the 50-day MA of 4097.40, and below the 200-day MA of 4334.49, indicating a neutral trend. The MACD of -4.18 indicates Positive momentum. The RSI at 50.68 is Neutral, neither overbought nor oversold. The STOCH value of 24.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4547.
Kissei Pharmaceutical Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ¥112.63B | 12.86 | 5.81% | 2.34% | 14.72% | 52.55% | |
64 Neutral | ¥166.45B | 12.18 | 6.37% | 2.60% | 10.35% | 16.60% | |
63 Neutral | ¥143.53B | 14.74 | 1.46% | 4.85% | -6.86% | -17.71% | |
52 Neutral | ¥61.64B | 31.19 | ― | 4.71% | -4.71% | -78.91% | |
52 Neutral | ¥161.17B | 21.52 | ― | 2.28% | 11.08% | 701.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥191.20B | 23.58 | 2.92% | 2.14% | 6.78% | -48.34% |
* Healthcare Sector Average
JP:4547
Kissei Pharmaceutical Co
4,105.00
-43.10
-1.04%
JP:4521
Kaken Pharmaceutical Co
3,990.00
360.55
9.93%
JP:4553
Towa Pharmaceutical Co
3,930.00
1,022.56
35.17%
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,290.00
236.34
7.74%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,170.00
-291.28
-19.93%
JP:4887
SAWAI GROUP HOLDINGS Co., Ltd.
1,611.00
-233.70
-12.67%
Kissei Pharmaceutical Co Corporate Events
Kissei Pharmaceutical Finalizes Adjusted Treasury Share Disposal for Employee Stock Plan
Aug 10, 2026
Kissei Pharmaceutical has completed payment for the disposal of treasury shares under a restricted stock scheme for its Employee Shareholding Association. The move is part of an internal shareholding system designed to reinforce employee ownership...
Kissei Pharmaceutical Reports No Treasury Share Purchases in July Under Ongoing Buyback Plan
Aug 6, 2026
Kissei Pharmaceutical has reported that it did not purchase any of its own shares in July 2026, despite having an ongoing board-approved share buyback program. The authorized program allows for acquisitions of up to 1.3 million shares, or about 3....
Kissei Pharmaceutical Cuts Earnings Forecasts on Weak TAVNEOS Sales
Jul 31, 2026
Kissei Pharmaceutical has cut its consolidated forecasts for the six months ending September 30, 2026 and the fiscal year to March 31, 2027, citing weaker-than-planned sales of its vasculitis drug TAVNEOS. Net sales for the interim period are now ...
Kissei Pharmaceutical Highlights Q1 FY2026 Results and R&D Pipeline Focus
Jul 31, 2026
Kissei Pharmaceutical Co. is a Japan-based drug maker listed on the Tokyo Stock Exchange under stock code 4547. The company operates in the pharmaceutical industry, focusing on the development, manufacture and sale of prescription medicines, suppo...
Kissei Pharmaceutical Posts Mixed Q1 Results, Lifts Dividends but Cuts FY2027 Outlook
Jul 31, 2026
Kissei Pharmaceutical reported a 5.4% rise in net sales to ¥23.39 billion for the quarter ended June 30, 2026, while operating profit fell 48% and ordinary profit dropped 25%, even as profit attributable to owners of parent edged up 4.5%. The...
Kissei Pharmaceutical Completes Treasury Share Disposal for Executive Restricted Stock
Jul 23, 2026
Kissei Pharmaceutical has completed a planned disposal of treasury shares used as restricted stock compensation for its leadership. The company disposed of 19,794 common shares at ¥3,940 per share, for total proceeds of ¥77,988,360, allo...
Kissei Pharmaceutical Reports No Share Buybacks Yet Under 2026 Repurchase Program
Jul 3, 2026
Kissei Pharmaceutical has reported the status of its ongoing share buyback program, authorized by its board in May 2026, confirming that no treasury shares were acquired between June 1 and June 30, 2026, despite having approval to purchase up to 1...
Kissei Faces EU Setback as EMA Backs Revocation of TAVNEOS Authorization
Jun 28, 2026
Kissei Pharmaceutical said European regulators have recommended revoking the EU marketing authorization for TAVNEOS, an avacopan-based oral therapy for microscopic polyangiitis and granulomatosis with polyangiitis, after a review raised concerns a...
Kissei Pharmaceutical Grants Restricted Stock to Board Members and Officers
Jun 23, 2026
Kissei Pharmaceutical has approved the disposal of 19,794 treasury shares as restricted stock to eight internal board members and twelve corporate officers, at a price of ¥3,940 per share for a total of about ¥78 million. The move is par...
Kissei Pharmaceutical Sets Share Buyback Framework but Executes No Purchases in May
Jun 3, 2026
Kissei Pharmaceutical reported that, during the period from May 12 to May 31, 2026, it did not repurchase any of its own common shares under a previously authorized buyback program. The company had obtained board approval in May to buy back up to ...
Kissei Files Japan NDA for IDH1-Targeting AML Drug Olutasidenib
May 27, 2026
Kissei Pharmaceutical has filed a new drug application in Japan for olutasidenib, a targeted therapy for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation, seeking approval to manufacture and market the drug domestical...
Kissei Tightens Safety Warnings on TAVNEOS After Serious Liver Risk Cases
May 21, 2026
Kissei Pharmaceutical has revised the Japanese package insert for its rare-disease drug TAVNEOS to highlight the risk of serious hepatic dysfunction, including vanishing bile duct syndrome and reported fatal cases. The update, prompted by Ministry...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.